Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

November 2015

Specialty Pharmacy Program Updates


Effective immediately, the following medications will be available from Accredo Specialty Pharmacy and no longer available at Magellan Health (formally ICORE). Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications for both the Premium and Value formularies.

Name Indication Coverage Available From

Soliris (eculizumab) 

Soliris is a terminal complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.  Medical Benefit Accredo

Aldurazyme (laronidase) 

Aldurazyme is an enzyme replacement therapy indicated for the treatment of mucopolysaccharidosis 1 (MPS 1).

Medical
Benefit
Accredo

Cerezyme (imiglucerase)  and
VPRIV(velaglucerase alfa)

Cerezyme and VPRIV are injectable medications indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease. Medical Benefit Accredo

Elaprase (idursulfase) 

Elaprase is an IV infusion indicated to improve walking ability in people with mucopolysaccharidosis II (MPS II), or Hunter syndrome.  Medical Benefit Accredo

Fabrazyme (agalsidase beta) 

Fabrazyme is used to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types in patients with Fabry disease. Medical Benefit Accredo

Lumizyme (alglucosidase alfa) and
Myozyme (Alglucosidase alfa) 

Lumizyme and Myozyme are lysosomal glycogen-specific enzymes indicated for use in patients with Pompe disease. Medical Benefit Accredo

Naglazyme (galsulfase)

Naglazyme is an enzyme replacement therapy indicated for the treatment of mucopolysaccharidosis VI (MPS VI). Medical Benefit Accredo

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Medicare Advantage Stride (HMO) Updates and Reminders

Prior Authorizations for Medicare Advantage Stride (HMO) via NIA

Medicare Advantage Stride (HMO) Gender Reassignment Services

New 2016 Medicare Advantage Stride (HMO) Benefits

Hospital Discharge Notifications Reminder

ICD-10 Reminder and Provider Support

HCAS Credentialing Best Practices Guide Now Available

Affordable Care Act and Risk Adjustment

CLINICIAN CORNER

Reminder: Referral Procedure Change for Massachusetts Providers

Identifying and Treating Postpartum Depression

Prior Authorization Required for Rexulti

Prior Authorization Required for Zecuity

P&T Committee Updates

Specialty Pharmacy Program Updates

OFFICE ASSISTANT

Reminder: Keep Panel Status Up to Date

Reminder: Bill National Drug Codes (NDC) For Unlisted Drugs

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator